Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review

Xu Jing; Wang Min; Liu Xia; Li Shanshan

doi:10.3389/fimmu.2025.1591631

Frontiers in Immunology (Jun 2025)

Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review

Xu Jing,
Wang Min,
Liu Xia,
Li Shanshan

Affiliations

Xu Jing: Department of Cardiology, State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Wang Min: Department of Hematology, China-Japan Friendship Hospital, Beijing, China
Liu Xia: Department of Rheumatology, Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, China
Li Shanshan: Department of Rheumatology, Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, China

DOI: https://doi.org/10.3389/fimmu.2025.1591631
Journal volume & issue: Vol. 16

Abstract

Read online

Ruxolitinib is a selective JAK1/2 inhibitor, and its application in treating adult-onset dermatomyositis(DM) has rarely been described. Here, we report a case of an adult-onset DM patient with anti-TIF1γ antibody, who also suffered from essential thrombocytosis related to the JAK2 V617F mutation. Her clinical symptoms of DM markedly improved after ruxolitinib treatment, whereas her platelet count did not significantly change. In addition, we reviewed previous studies on the treatment of adult DM with ruxolitinib, and summarized reports of the JAK2 V617F mutation in adult idiopathic inflammatory myopathy.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords